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ABSTRACT: The systematic shortening of the noncovalent element of a C8-linked
pyrrolobenzodiazepine (PBD) conjugate (13) led to the synthesis of a 19-member
library of C8-PBD monomers. The critical elements of 13, which were required to
render the molecule cytotoxic, were elucidated by an annexin V assay. The eﬀects of
shortening the noncovalent element of the molecule on transcription factor
inhibitory capacity were also explored through an enzyme-linked immunosorbent
assay-based measurement of nuclear NF-κB upon exposure of JJN-3 cells to the
synthesized molecules. Although shortening the noncovalent interactive element of
13 had a less than expected eﬀect upon compound cytotoxicity due to reduced DNA
interaction, the transcription factor inhibitory capacity of the molecule was notably
altered. This study suggests that a relatively short noncovalent side chain at the C8
position of PBD is suﬃcient to confer cytotoxicity. The shortened PBD monomers
provide a new ADC payload scaﬀold because of their potent cytotoxicity and drug-
like properties.
■ INTRODUCTION
Since their discovery in Streptomyces bacteria over half a
century ago, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) struc-
tures have been of interest as possible chemotherapeutic
agents. This is due to their ability to sequence selectively bind
covalently to DNA, to cause DNA strand cleavage, and to
inhibit DNA-associated enzymes.1−3 Two critical features of
the PBD structure confer this covalent binding capacity on the
molecule. S stereochemistry at the C11a position of the
molecule bestows a right-handed longitudinal twist upon the
structure, allowing an eﬀective ﬁt along the minor groove of
the DNA helix.4,5 Complementing this optimal ﬁt is the
presence of an interconvertible imine-carbinolamine moiety at
the N10−C11 position of the molecule. This electrophilic
center undergoes attack from the C2−NH2 of guanine bases in
the minor groove, forming the covalent aminal bonds
responsible for their potent cytotoxicity6−8 (Figure 1A).
PBD structures have been found to form covalent bonds
with some guanines in the DNA minor groove more frequently
than others, particularly those ﬂanked by purine bases,5,9
although more recent data suggest kinetic preferences when
guanines are ﬂanked by pyrimidines.10 This potential for
relative selectivity of binding is of interest, given that the
pathogenesis of many cancers is associated with the aberrant
binding of transcription factors, such as nuclear factor kappa B
(NF-κB), to sequence-speciﬁc promoter regions of DNA.11−15
The conjugation of subunits, capable of noncovalent
interactions with DNA bases, to the C8 position of the PBD
structure (via a carbon linker of variable length) has led to the
development of hybrid molecules that can interact selectively
with longer sequences of DNA than the typical purine−
guanine−purine motifs of unmodiﬁed PBD structures. Such
molecules have shown a capacity to inhibit the binding of
transcription factors, such as NF-Y16 and NF-κB17 to their
respective promoter sequences. More recent C8-modiﬁed
PBDs, such as KMR-28-39 (Figure 1B) synthesized by
Rahman and co-workers18 have demonstrated the evidence
of preclinical activity of such PBD conjugates. In addition to
their cytotoxicity and anti-tumor activity, PBD-heterocyclic
hybrids have shown signiﬁcant antimicrobial activity.19−21
More recently, PBDs are being used as cytotoxic payloads for
antibody−drug conjugates, and a number of these are currently
undergoing clinical evaluation.22
Although the addition of noncovalent interactive subunits to
the C8 position of PBD structures has been associated with the
down-regulation of genes downstream of transcription factor
activity,17,18,23,24 the relationship between the structural
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requirements and the potent cytotoxicity observed for these
molecules has not been fully elucidated. The extent of C8
diversiﬁcation required to confer this transcription factor
activity (i.e., the core noncovalent interactive pharmacophore)
remains unclear. In this paper, we investigated some of these
uncertainties through the systematic shortening of a C8-linked
monomer (13, Figure 1C) containing a pyrrole−benzofuran
motif which has been previously explored in both noncovalent
distamycin25 and covalent duocarmycin analogues26 and the
subsequent generation of a library of 19 C8-linked PBD
monomers. The eﬀect of the reduction of the noncovalent
element of the hybrid on both transcription factor activity and
overall cytotoxicity was then evaluated.
Figure 1. (A), The three-ring structure of the PBD core, with key atoms labelled. (B), The structure of KMR-28-39, with the PBD component
highlighted in blue. (C), The shortening strategy for 13, which underpinned the development of the novel PBD hybrids, is detailed in this paper.
Scheme 1. Conjugation of the Non-Covalent Element of the PBD Hybrid and Activation of the N10−C11 Imine
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■ RESULTS AND DISCUSSION
Synthesis of PBD Hybrids. The PBD core (N10-Alloc,
C11-THP protected) of the hybrids (10) was synthesized from
vanillin, as previously described in the literature18 (see the
Supporting Information for scheme). A four-carbon linker was
used to connect the PBD component with the noncovalent
interactive subunits, as chains of this length had proven
optimal for DNA binding in previous hybrid SAR studies. The
linker was located at the C8 position of the molecule to allow
an isohelical ﬁt of the noncovalent component of the hybrid
along the minor groove upon covalent PBD binding.2
After the synthesis of the PBD core, the C8 hybrid 13 was
constructed using a combination of a benzofuran and an N-
methyl pyrrole moiety. This was based upon the molecular
structures of the side chains of KMR-28-39 (Figure 1B) and
other molecules recently described by Basher and co-
workers.27 These benzofuran−pyrrole components were linked
via Steglich amide bond formation at positions that maintained
the overall ﬁt of the hybrid for the DNA minor groove (i.e.,
C2/C5 for benzofuran, C1/C4 for N-methyl pyrrole
components). The full synthesis of the noncovalent interactive
hybrid component of 13 is summarized in the Supporting
Information, with the conjugation to the PBD moiety and
activation of the N10−C11 imine component of the molecule
detailed in Scheme 1. A total of 19 new PBDs were synthesized
by the systematic shortening of the noncovalent interactive
element of 13 (Table 1). This process was analogous to the
synthesis of 13, with component 11, replaced with designed
building blocks to aﬀord progressively shortened C8-PBDs.
Biological Evaluation. Cytotoxicity Screening. Given the
established inhibition of the activity of the NF-κB transcription
factor by previous (structurally similar) C8-linked PBD
monomers, such as those described by Rahman and co-
workers,18 it was hypothesized that compound 13 and its
shortened derivatives could share such properties. Accordingly,
the initial screening of the compounds was carried out in
primary tumor samples and a malignant cell line known to
manifest aberrant activity of NF-κB. The pathogenesis of both
chronic lymphocytic leukemia (CLL) and multiple myeloma
has been linked to aberrant gene expression mediated, at least
in part, by NF-κB.28−33 Primary tissues were obtained from
CLL patients (n = 3) with their informed consent, and the
authenticated multiple myeloma cell line, JJN-3, was purchased
from DSMZ (Germany). The compounds were added to
cultures of the primary CLL cells and JJN-3 cells at
concentrations between 1 nM and 100 μM in both primary
leukemic cells and the cell line for 48 h. An annexin V binding
assay was used to measure cytotoxicity, and LC50 values were
calculated from the sigmoidal dose−response curves using
Table 1. Evaluation of the C8 Hybrid 13 and Its Shortened Derivatives in Primary CLL Cells and JJN-3 Cell Linesa
aLC50 values were calculated from sigmoidal dose−response curves generated from three independent experiments, performed in duplicate.
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Prism 6.0 software. A previously synthesized C8-linked PBD
hybrid featuring transcription factor inhibitory properties,
GWL-78,34 was also evaluated as a positive control. The
results of this cytotoxicity evaluation are described in Table 1,
with the cytotoxicity dose−response curves obtained for each
molecule detailed in the Supporting Information.
Prior to the screening of the shortened compound library in
the CLL and JJN-3 cell cultures, it was expected that molecular
shortening of the side chain of 13 would diminish compound
activity. This was based upon the hypothesis that both the
overall aﬃnity of the PBD hybrid for DNA and the length of
DNA sequences bound by the compound would be reduced
because of the reduction in noncovalent interactions between
the DNA minor groove and the C8 side chain of the molecule.
This concept has been reﬂected in the cytotoxicity of
previously synthesized PBD hybrids, which featured short
C8-conjugated moieties. Such compounds either lacked
notable cytotoxicity or were less cytotoxic than their longer
side-chain counterparts. Examples of these compounds include
a PBD hybrid containing a single pyrrole element synthesized
by Borgatti and co-workers, as well as hybrids of similar
structure by Thurston and co-workers, which were only weakly
cytotoxic.34,35
The cytotoxicity of the compounds in the primary CLL cells
and the JJN-3 cell line was therefore unexpected. For several of
the compounds tested, LC50 values were obtained in the low
nanomolar range, with good concordance in cytotoxicity
observed between the primary CLL cells and the myeloma
cell line. In total, 10 compounds maintained or improved
activity with respect to 13 upon side chain shortening in
primary CLL cells.
The cellular screen provided some insight into the structural
features of the noncovalently interactive C8 side chain of 13
which may prove integral to its cytotoxic activity. It appeared
that the presence of the terminal pyrrole moiety of 13 is not
essential for its activity, as cytotoxicity was largely preserved for
the benzofuran-containing compounds 14 and 15. Aromaticity
of the furan component of the benzofuran structure also
appeared not to be crucial for its cytotoxicity. Indeed, the
dihydrobenzofuran-containing compound, 16, was one of the
most cytotoxic compounds tested in primary CLL cells.
Opening this furan ring also maintained activity at low
nanomolar levels in both primary CLL cells and the JJN-3 cell
line.
The importance of the oxygen moiety of benzofuran is less
clear from this cellular evaluation. Replacement of the oxygen
atom with a carbon (17) or its complete elimination (22−24)
had little eﬀect upon compound activity. This indicates that
the potential hydrogen bond acceptor role of the oxygen plays
little part in the overall cytotoxicity of 13. Interestingly,
reduced cytotoxicity was observed for 21. In this case, the
benzofuran oxygen is present as part of a phenol, rather than
an ether functional group. The phenol moiety of 21 may act as
a hydrogen bond donor, in contrast to its ether-containing
analogues. The latter of these characteristics appeared to have
an important eﬀect on overall cytotoxicity.
Interestingly, the entire removal of the furan ring of the
benzofuran side-chain component (25) failed to appreciably
reduce the cytotoxicity. However, alterations to the benzene
element of the benzofuran had more signiﬁcant eﬀects upon
cytotoxicity. The introduction of a nitrogen atom into the ring,
through the use of aminopyridine building blocks, eliminated
compound activity at the dose range tested. Such a deleterious
eﬀect upon compound activity was unexpected. In a similar
fashion to the introduction of the phenol group in 21, the
nitrogen of the pyridine ring may ionize depending upon the
pH conditions. In a mildly acidic environment, the pyridine
ring is protonated (pKa of the conjugate acid is around 5.72),
creating a formal positive charge. This charge may aﬀect the
ability of the molecule to penetrate the cell membrane and
reach the minor groove of DNA. Moreover, the charged
conjugate acid also conferred another hydrogen bond donor
group on the molecule. One or both of these eﬀects are likely
to impact upon the activity of the PBD hybrids 26 and 27,
which showed approximately a three-log reduction in
cytotoxicity when compared to 13.
Removal of the aromaticity of this ring notably reduced the
cytotoxicity. The cyclohexane and ring-opened derivatives
(28−32) showed poor activity in both primary CLL cells and
the JJN-3 cell line. It is possible that the spatial alteration of
this portion of the side chain from a planar sp2 hybridized
structure to sp3 derivative was responsible for this loss of
activity. The removal of the delocalized electrons of the
aromatic system may also have aﬀected compound activity
because of the removal of potential π−π interactions with
DNA bases.
Given the surprisingly similar cytotoxicity of 13 and its
shortened derivatives in the CLL primary tissue and JJN-3 cell
line evaluations, it was decided to conduct an evaluation of the
shortened PBD hybrids versus their parent 13 in healthy age-
matched B- and T-cell cultures. This would establish whether
the cytotoxicity observed in the malignant cells was mirrored in
non-malignant cells and whether a notional therapeutic index
was apparent. Six shortened derivatives of 13, which showed
potent cytotoxicity in the initial CLL and JJN-3 cellular
screens, were chosen for evaluation in the healthy cells: 14, 15,
18, 19, 20, and 28. Normal peripheral blood B-cells and T-
cells, derived from three donors, were incubated with the seven
compounds for 48 h at concentrations ranging from 1 nM to
100 μM. Subsequently, the cells were harvested by
centrifugation, and apoptosis was quantiﬁed using an annexin
V assay. The cytotoxicity dose−response curves obtained are
detailed in the Supporting Information, with Table 2 listing the
LC50 values obtained in both normal B- and T-cells, as well as
the relative toxicity in these cells compared to primary CLL
cells.
All of the compounds tested showed cytotoxicity ranging
from 0.39 to 12.4 μM in both cell types. The compounds
showed diﬀerential toxicity in the primary CLL cells compared
to the normal B-cells and normal T-cells with notional
therapeutic indices between 1 and 2 logs. The least potent
Table 2. LC50 Values of 13 and Its Shortened Derivatives
with Calculated Therapeutic Indices Relative to Primary
CLL Cell Cytotoxicity
compound
normal
B-cell LC50
(nM)
normal
T-cell LC50
(nM)
B-cell/CLL
therapeutic
index
T-cell/CLL TI
therapeutic
index
13 930 1700 124 226.7
14 410 2100 46.1 236
15 1400 3900 148.9 414.9
18 390 1100 45.9 129.4
19 750 3000 129.3 517.2
20 640 690 71.9 77.5
28 1700 12 400 0.24 1.74
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compound tested, 28 showed no therapeutic index. Overall,
the compounds showed better therapeutic indices against T-
cells compared to B-cells with average therapeutic indices of
229.1 and 80.9, respectively. The observed therapeutic indices
are large enough to consider further development of these C8-
linked PBDs. However, there was no correlation between
therapeutic indices and the length of the molecules. Essentially,
this healthy cell evaluation conﬁrmed that extensive shortening
of the noncovalent component of 13 did little to aﬀect either
the cytotoxicity or selectivity proﬁle of the compounds.
Evaluation of the Eﬀects of 13 and Derivatives on
Nuclear Levels of NF-κB. Given the lack of observable
cytotoxicity diﬀerences between 13 and all but its most
shortened C8-side-chain derivatives, it was decided to evaluate
whether the reduction of the C8-linked noncovalent interactive
side chain had any eﬀect upon potential transcription factor
inhibition by compound 13.
The potent cytotoxicity observed for 13 and its derivatives in
a number of NF-κB-dependent cancer cell types provided
indirect evidence for their potential as possible inhibitors of
this transcription factor. Moreover, the previously reported
cellular inhibition by similar PBD hybrids of NF-κB17,18,36
provided further impetus to directly measure the potential of
these novel C8-linked PBD monomers to alter the nuclear
levels of this transcription factor.
As a result, the eﬀect of 13 and ﬁve of its shortened
derivatives (15, 19, 20, 21, and 25), on nuclear levels of NF-κB
in JJN-3 cells, was investigated. The derivative compounds
were chosen because of their potency and to provide
representative examples of the various stages of the shortening
of the noncovalent interactive component of the compound.
JJN-3 cell lines were chosen over the primary CLL cell samples
for this analysis as the levels of nuclear NF-κB were more
consistent in this cell line compared to primary tumor cells
derived from diﬀerent patients.
The measurement of the eﬀects of the four compounds on
nuclear levels of NF-κB involved the use of an adapted
enzyme-linked immunosorbent assay (ELISA). Nuclear
Figure 2. The eﬀect of compounds 13, 15, 19, 25, 28 and GWL-78 on canonical NF-κB subunits after 4 h exposure.
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extracts were prepared from treated and control cells using a
nuclear extraction kit (Active Motif). Activated NF-κB
subunits (p65, RelB, p52 or p50) in the samples were
measured by oligonucleotide-based ELISA (Active Motif).
Treated and control samples were incubated in the wells of a
96-well microtiter plate that were coated with the NF-κB
consensus nucleotide sequence (5′-GGGACTTTCC-3′). NF-
κB from the cell samples attached to the wells and was
captured by speciﬁc antibody to either p65, RelB, p50 or p52.
Binding of the speciﬁc NF-κB family member was then
detected by an anti-rabbit-HRP-conjugated antibody. Devel-
oping solution was then added to the plate for 5 min prior to
the addition of stop solution. The intensity of the developed
color was proportional to the quantity of p65, RelB, p50 or p52
in each sample, and the amount of bound NF-κB was
quantiﬁed (ng/μg nuclear extract) from subunit recombinant
protein standard curves. The speciﬁcity of binding to the
nucleotide sequence was ascertained by premixing free
consensus nucleotide to the sample before adding the nuclear
extract to the well. Sample determinations were normalized by
the total cellular protein, as determined by the protein assay kit
(Pierce). Data were expressed as a percentage of the untreated
controls.
The quantiﬁed DNA binding activity for each NF-κB
subunit in cells exposed to 13, 15, 19, 20, 21 and 25 was
then related to a control value obtained from cells that had not
been exposed to a PBD hybrid. The experiment was repeated
in triplicate, and the eﬀect of the compounds upon DNA
binding of four subunits of NF-κB is illustrated in Figures 2
and 3 below. The c-Rel subunit was not evaluated in these
experiments.
The evaluation of the eﬀects on nuclear levels of NF-κB by
the shortened PBD hybrids produced some interesting results.
The signiﬁcant knockdown of p65 by 15 aside, the shortened
compounds tested produced no signiﬁcant reductions in
nuclear levels of the p65 subunit activity, despite their highly
potent cytotoxicity in JJN-3 cells. When placed in the context
of the role of NF-κB subunit function in carcinogenesis, this
was an interesting outcome. p65 overexpression has been
implicated in the progression of malignancy; a previous
analysis of a cohort of CLL patient samples revealed signiﬁcant
up-regulation of the p65 subunit28 and this was associated with
disease progression.37
Figure 3. The eﬀect of compounds 13, 15, 19, 25, 28 and GWL-78 on non-canonical NF-κB subunits after 4 h exposure.
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The nuclear activity of p52 was unaﬀected or increased (13
and 19) by the PBD hybrids, whereas the RelB subunit was
signiﬁcantly decreased by 13, but not by the shortened
derivatives. Interestingly, all three of the shortened compounds
tested signiﬁcantly reduced p50 levels. This was not the case
for 13. However, the role of p50 in carcinogenesis is to date ill-
deﬁned,38 and in some cases, increased levels of the subunit
may promote apoptotic pathways.39 Accordingly, the diﬀer-
ential capacity of the PBD hybrids to inhibit the p65 subunit
was considered in greater detail.
An evaluation of the structures of the three compounds
(Figure 2) tested in this assay may help explain the diﬀerences
in eﬀect upon nuclear levels of NF-κB observed, especially the
levels of p65. The parent 13 PBD hybrid molecule showed
consistent inhibition of nuclear p65 activity. Compound 15,
which also signiﬁcantly inhibited the p65 subunit, shares the
greatest side chain similarity with 13 of the three compounds
tested. The 15 side chain retains an intact benzofuran moiety
common to its predecessors. This benzofuran is disrupted in
19 and 25, with both the aromaticity and rigid cyclic structure
of the furan ring of the benzofuran removed. Both compounds
showed no discernible eﬀect on nuclear p65 levels, despite
their potency.
The results of this assay provided a more subtle insight into
potential mechanisms of activity of PBD hybrids than a
reliance on cell cytotoxicity assays alone. Although all of the
compounds tested showed promising potency characteristics in
a range of cancer cell lines, their NF-κB transcription factor
inhibitory eﬀects diﬀered depending upon the side-chain
composition. Compound 13, containing the longest non-
covalent interactive element, displayed the most eﬀective
inhibition of NF-κB and eﬀects upon nuclear p65, and RelB
levels appeared to diminish in tandem with the reduction of
this element in the derivatives 15, 19, and 25 (although some
increased inhibition of p50 was observed).
The clear diﬀerences in the NF-κB inhibitory capacity
observed through the systematic shortening of 13 contrasted
with the relatively comparable cytotoxicity proﬁles of all but
the most shortened library derivatives. Two possible
explanations may help explain this incongruity.
First, it is possible that the eﬀects of the noncovalent
interactive elements of the PBD hybrids on nuclear NF-κB
activity are unrelated to their cytotoxic mechanism of activity.
Such an assessment would regard the PBD monomers
primarily as traditional DNA alkylating agents, with the
transcription factor inhibitory eﬀects (such as the p65
inhibition), displayed by molecules such as 13 eﬀects, rather
than the causes of PBD cytotoxicity. In this scenario, the
noncovalent element of the molecules merely serves to confer
diﬀerent physicochemical properties on the compound or alter
the nuclear penetration rate and extent of adduct formation
with DNA.
The second, more compelling explanation for diﬀerences in
the transcription factor inhibitory activity between PBD
hybrids with varying noncovalent interactive elements is
slightly more nuanced. Although all PBD molecules feature
an ability to bind covalently to DNA and act to some extent as
traditional alkylating agents, some may do so in a relatively
more selective manner than others. It may be argued that the
shortened derivatives of 13, such as 25, which feature short,
low molecular weight side chains, bind to guanines along the
minor groove indiscriminately. It is unlikely that such
shortened structures (which form adducts spanning c. 4−5
DNA bases) would feature either the aﬃnity or diameter to
speciﬁcally disrupt conserved 8−9 base transcription factor
promotor sequences. On the other hand, the presence of
longer noncovalent interactive elements (such as those found
in 13) conjugated to PBD structures may subtly alter their
binding distribution along the minor groove. By adding
moieties capable of interacting noncovalently with DNA
sequences in a relatively selective manner, the covalent adducts
of PBD structures may be (to some extent) preferentially
directed toward the longer, more speciﬁc sequences of DNA
that are bound by transcription factors. Although the
traditional eﬀects of nonselective alkylation undoubtedly still
occur, additional mechanisms of cell disruption (such as
transcription factor inhibition) may also underpin the
cytotoxicity of molecules such as 13.
2D QSAR Analysis. A two-dimensional quantitative QSAR
study of all compounds was carried out using a multiple linear
regression (MLR) method to determine if there are any
correlations between the biological activity (1/LC50) and
physicochemical descriptors log P, molecular weight, steric
factors, and electronic factors. Leave-one-out cross validation
was the regression method applied in the MLR model to study
the correlation of the descriptors and the LC50 of the
compounds. The results are listed in Table 3. The study
showed slightly better correlation between the biological
activity of the molecules in primary CLL cells (0.63) compared
to JJN-3 cell lines (0.52). The correlation improved when only
log P (0.74) or molecular weight (0.68) was considered in
primary CLL cells. However, the correlations between
biological activity in JJN-3 cell line and log P (0.58) or
molecular weight (0.48) were moderate.
Molecular Modeling with DNA Sequences. As all of the
compounds including the shortened compounds are expected
to exert their cytotoxicity by covalent bonding with DNA and
subsequent inhibition of transcription factors, a molecular
modeling study was carried with four compounds (13, 20, 23,
and 32) with diﬀerent C8 side-chain lengths and one AT-rich
and one GC-rich DNA sequences. These compounds represent
a mix of longer and shorter PBD compounds synthesized with
a range of cytotoxicities. The molecular docking study
suggested that all four compounds are able to snugly bind
with the DNA minor groove and retain the shape character-
istics required for the DNA minor groove binding molecules
(Figures 4, S3 and S4). The energy of binding calculation
showed the highest value for compound 13 with −11 KJ/mole
for AT-rich DNA and −10.7 KJ/mol for the GC-rich DNA.
Table 3. 2D QSAR Parameters Showing Correlation
between Biological Activity (1/LC50) of PBD Hybrids in
Primary CLL Cells and JJN-3 Cell Line and All
Physiochemical Descriptors Determined Using MLR
Modela
primary CLL cells JJN-3 cell line
RMSEcv 0.98 1.03
R2 cv 0.63 0.53
RMSEc 0.50 0.47
R2cal 0.88 0.87
aRMSEcv: root mean square errors of error for cross validation; R2cv:
regression coeﬃcient for cross validation; RMSEc: root mean square
errors of error for calibration; R2cal: regression coeﬃcient for
calibration.
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The values obtained for 20 and 23 were comparable, and the
value for compound 32 was slightly lower (Table S1). The
ﬁndings of the study broadly support the experimental
observation as the shortened molecules retained their ability
to interact with DNA sequences. However, the relative lack of
activity of compound 32 cannot be explained by modeling
alone as the physicochemical property of the molecule likely to
have played an important role in the overall activity of the
molecule.
■ CONCLUSIONS
The systemic shortening of the C8 side chain of PBD
monomers show that transcription factor inhibitory eﬀects may
not necessarily translate into increased overall cytotoxicity or
tolerability in vitro for PBD-type molecules. This observation
may be useful in the design of monoalkylating PBD monomers
that are currently being explored as standalone anticancer
agents and payloads for antibody−drug conjugates. It is
possible, however, that diﬀerential tolerability eﬀects may only
manifest themselves in in vivo evaluations. Indeed, the high
therapeutic index of historical PBD hybrids (featuring longer
noncovalent interactive elements of structure similar to that of
13) versus unsubstituted PBD cores39 provides the rationale
for in vivo investigations of the novel PBD structures described
in this paper. Such evaluations are currently underway.
■ EXPERIMENTAL SECTION
Synthesis. General Material and Methods. Synthetic building
blocks, reagents, solvents, and chemicals were purchased from Sigma-
Aldrich, Fluorochem, Fisher Scientiﬁc, Alfa Aesar, and Bachem,
respectively. All reactions carried out were monitored by thin-layer
chromatography carried out on E. Merck silica gel 60 F254 plates
(0.25 mm). The plates were visualized using UV light at 254 nm and
potassium permanganate staining where required. Puriﬁcation using
ﬂash column chromatography was carried out using standard glass
columns and silica gel as a stationary phase (Merck 60, 230−400
mesh ASTM). Where freeze drying of intermediates/ﬁnal compounds
was carried out, this was done using a Heto-Lyolab 3000 freeze dryer.
High-performance liquid chromatography coupled to mass spectrom-
etry was carried out on reaction mixtures, intermediates, and ﬁnal
products. This analysis was performed on a Waters Alliance 2695
separation system using water (solvent A) and acetonitrile (solvent B)
as mobile phases using a Monolithic C18 50 × 4.60 mm column by
phenomenex. UV detection was performed on a diode array detector.
Formic acid was used to ensure acidic conditions throughout the
analysis and was used at concentrations of 0.1%.
All of the compounds tested for their biological activity are >95%
pure, conﬁrmed with two diﬀerent HPLC analysis methods. A 10 min
(method A) and 5 min (method B) gradient was used to analyze
submitted samples. The ﬂow rate for both was 0.5 mL/min; 200 μL
was split over a zero dead volume T piece which passed into the mass
spectrometer. The wavelength range of the UV detector of the HPLC
system was 220−400 nm. The function type used was a diode array
(535 scans). The column type was a monolithic C18 50 × 4.60 mm
column.
Method A (10 min run). 95% A 5% B for 2 min increasing to 50%
B over 3 min. The gradient was then held at 50% B for 1 min and then
increased to 95% B over 1.5 min. The quantity of B was then returned
to 5% B over 1.5 min and held for 1 min.
Method B (5 min run). 95% A 5% B at 0 min increasing to 90% B
over 3 min. The gradient was then increased to 95% B over 0.5 min
Figure 4. (A) The structures of the C8-PBD hybrids evaluated in the molecular modelling study; overlaid molecular docking images of PBD
hybrids with (B) AT-rich and (C) GC-rich DNA sequences.
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and then held for 1 min. The quantity of B was then returned to 5% B
over 0.5 min.
High-resolution mass spectrometry was undertaken on all ﬁnal
compounds synthesized. This was carried out using a Waters
Micromass QTOF Global system in positive W-mode. Compounds
were dissolved in DMSO at concentrations of 5 mM and introduced
into the instrument using metal-coated borosilicate glass tips. 1H
NMR and 13C NMR were carried out on a Bruker ADVANCE NMR
spectrometer. The proton NMR was run at 400 Hz, whereas the
carbon samples were run at 100 Hz. The temperature for all samples
was 300 K. The spectra obtained for each sample were processed and
analyzed using Topspin 3.0.
Synthesis of PBD Core, C8-Tails and C8-Linked PBD-Imines.
PBD core 10 was synthesized following the literature procedure in
nine steps in good yield. The intermediates were puriﬁed and fully
characterized before progressing to the next step (Supporting
Information).
Synthesis of Methyl 4-(5-Aminobenzofuran-2-carboxamido)-1-
methyl-1H-pyrrole-2-carboxylate (11). 5-((tert-Butoxycarbonyl)-
amino)benzofuran-2-carboxylic acid (0.5 g, 1.80 mmol) was dissolved
in dimethylformamide (DMF) (3 mL). EDCI (0.70 g, 2 equiv) and
DMAP (0.69 g, 2.5 equiv) were added to the reaction mixture, and
the solution was stirred for 30 min. Methyl 4-amino-1-methyl-1H-
pyrrole-2-carboxylate (0.40 g, 1.5 equiv) was then added to the ﬂask,
and the reaction mixture left overnight. After thin-layer chromatog-
raphy (TLC) (20% ethyl acetate/DCM) and LC−MS showed
completion of reaction, the reaction mixture was placed in ice water
(30 mL) and extracted with ethyl acetate (3 × 50 mL). The ethyl
acetate layers were combined and washed with citric acid solution (50
mL), bicarbonate solution (50 mL), water (50 mL), and brine (50
mL). The solution was concentrated in a rotary evaporator to yield
brown oil. The crude material was brieﬂy characterized by LC−MS
before the Boc protected material was dissolved in methanol (1 mL
for every mg of starting material), and 4 M HCl in dioxane (2 mL for
every 25 mg of starting material). Gas evolution was observed. After 1
h, the reaction was found to be complete via LC−MS and TLC (20%
ethyl acetate/DCM). The solution was concentrated using a rotary
evaporator to yield the deprotected compound 11 as the hydrochloric
acid salt in good yield (64% over two steps). 1H NMR (400 MHz,
(CD3)2SO): δ 10.87 (s, 1H), 10.14 (bs, 2H), 7.81 (d, 1H, J = 8.8 Hz),
7.76−7.74 (m, 2H) 7.55 (d, 1H, J = 1.2 Hz), 7.36 (dd, 1H, J = 1.6 Hz,
8.8 Hz), 7.03 (d, 1H, J = 1.2 Hz), 3.87 (s, 3H), 3.76 (s, 3H). EIMS
(m/z): 314.0 (M + H)+.
Synthesis of Allyl (11aS)-7-methoxy-8-(4-((2-((5-(methoxycar-
bonyl)-1-methyl-1H-pyrrol-3-yl)carbamoyl)benzofuran-5-yl)-
amino)-4-oxobutoxy)-5-oxo-11-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-
10(5H)-carboxylate (12), and (S)-Methyl 4-(5-(4-((7-methoxy-5-
oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-
8-yl)oxy)butanamido)benzofuran-2-carboxamido)-1-methyl-1H-
pyrrole-2-carboxylate (13). 10 (0.132 g, 1.1 equiv) was dissolved in
DMF (3 mL). EDCI (0.085 g, 2 equiv) and DMAP (0.071 g, 2.5
equiv) were added to the reaction mixture, and the solution was
stirred for 30 min. 11 (0.07 g, 0.233 mmol) was then added to the
ﬂask, and the reaction mixture left overnight. After TLC (20%
acetone/DCM)/LC−MS showed completion of reaction, the reaction
mixture was placed in ice water (30 mL) and extracted with ethyl
acetate (3 × 50 mL). The ethyl acetate layers were combined and
washed with saturated citric acid solution (50 mL), bicarbonate
solution (50 mL), water (50 mL), and brine (50 mL). The solution
was concentrated in a rotary evaporator to yield brown oil. After
characterization by LC−MS only, the protected intermediate 12 was
then immediately deprotected to yield the imine. 12 (127 mg, 0.103
mmol) was dissolved in DCM (10 mL). To this solution,
Tetrakis(triphenylphosphine)palladium(0) (6 mg, 0.08 equiv),
triphenylphosphine (6.76 mg, 0.42 equiv), and pyrrolidine (10.93
μL, 2.0 equiv) were added. After approximately 30 min, the reaction
was observed to go to completion by LC−MS and TLC (50%
acetone/DCM) analysis. The solution was concentrated by rotary
evaporation to remove the solvent and pyrrolidine and the crude
immediately puriﬁed by ﬂash column chromatography using a DCM/
acetone mobile phase (75:25) yielding 100 mg 13 as a creamy white
solid in 64% yield (two steps). 1H NMR (400 MHz, CDCl3): δ 8.74
(s, 1H), 8.62 (s, 1H), 7.86 (d, 1H, J = 2.0 Hz), 7.66 (d, 1H, J = 4.4
Hz), 7.51 (d, 1H J = 2.0 Hz), 7.48 (s, 1H), 7.44 (dd, 1H, J = 2.0, 9.2
Hz), 7.38, (s, 1H), 7.31 (s, 1H), 6.91, (d, 1H, J = 2.0 Hz), 6.81 (s,
1H), 4.10 (t, 2H, J = 6.0 Hz), 3.87 (s, 3H), 3.81 (s, 3H), 3.780 (s,
3H), 3.72−3.67 (m, 2H), 3.65−3.53 (m, 1H), 2.63−2.59 (m, 2H),
2.35−2.20 (m, 4H), 2.08−1.95 (m, 2H). 13C NMR (100 MHz,
CDCl3): δ 171.2, 164.7, 162.7, 161.5, 155.8, 151.6, 150.5, 149.1,
147.6, 140.7, 134.4, 127.9, 121.4, 121.0, 120.7, 120.3, 120.0, 113.9,
111.7, 111.6, 110.8, 108.5, 68.1, 56.00, 53.8, 51.2, 50.7, 46.8, 36.9,
33.8, 29.6, 24.8, 24.2. HRMS m/z (+EI) calcd for C33H33N5O8 (M)
+,
628.2402; found, 628.2399. HPLC Method A: purity = >98%,
retention time = 6.33 min. Method B: purity = >98% retention time =
3.25 min.
This general method was utilized for the synthesis of compounds
14−32, with commercially available amino building blocks replacing
11. Yields over two steps for each compound are detailed below.
DCM/Acetone mobile phases were used during ﬂash column
puriﬁcation of all of the compounds, with the proportion of acetone
used depending upon the polarity of the compound.
(S)-Methyl 5-(4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamido)-
benzofuran-2-carboxylate (14). 1H NMR (400 MHz, CDCl3): δ
8.07 (d, 1H, J = 2.0 Hz), 7.81 (s, 1H), 7.67 (d, 1H, J = 4.4 Hz), 7.53
(s, 1H), 7.51 (s, 1H), 7.45 (s, 1H), 7.32 (dd, 1H, J = 2.0, 8.0 Hz),
6.84 (s, 1H), 4.25−4.14 (m, 2H), 3.98 (s, 3H), 3.86 (s, 3H), 3.86−
3.78 (m, 1H), 3.73−3.67 (m, 1H), 3.61−3.54 (m, 1H), 2.68−2.62
(m, 2H), 2.34−2.28 (m, 4H), 2.10−2.04 (m, 2H). 13C NMR (100
MHz, CDCl3): δ, 171.0, 164.6, 162.6, 159.9, 152.5, 150.4, 147.6,
146.1, 140.7, 134.3, 127.3, 121.1, 120.5, 114.2, 112.4, 111.6, 110.8,
68.0, 56.1, 53.7, 52.4, 46.7, 34.0, 31.0, 29.7, 24.8, 24.2. HRMS m/z
(+EI) calcd for C27H27N3O7 (M)
+, 506.1922; found, 506.1926.
HPLC Method A: purity = >98%, retention time = 6.18 min. Method
B: purity = >98%, retention time = 3.15 min. Yield = 52%, 67 mg
(over two steps), pale brown solid.
(S)-N-(Benzofuran-5-yl)-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahy-
dro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide
(15). 1H NMR (400 MHz, CDCl3): δ 8.07 (s, 1H), 7.88 (d, 1H, J =
2.0 Hz), 7.64 (d, 1H, J = 4.4 Hz), 7.58 (d, 1H, J = 2.0 Hz), 7.49 (s,
1H), 7.38 (d, 1H, J = 8.8 Hz), 7.22 (dd, 1H, J = 2.0, 8.8 Hz), 6.81 (s,
1H), 6.69 (s, 1H), 4.19−4.08 (m, 2H), 3.84 (s, 3H), 3.82−3.75 (m,
1H), 3.69−3.65 (m, 1H), 3.59−3.51 (m, 1H), 2.62−2.58 (m, 2H),
2.30−2.23 (m, 4H), 2.05−2.01 (m, 2H). 13C NMR (100 MHz,
CDCl3): δ 170.8, 164.6, 162.6, 151.9, 150.5, 147.7, 145.8, 140.7,
133.3, 127.7, 120.4, 117.7, 113.1, 111.6, 111.3, 110.8, 106.8, 68.0,
56.1, 53.7, 46.7, 33.9, 31.0, 24.9, 24.2. HRMS m/z (+EI) calcd for
C25H25N3O5 (M)
+, 448.1867; found, 448.1871. HPLC Method A:
purity = >98%, retention time = 6.07 min. Method B: purity = >98%,
Rretention time = 3.10 min. Yield = 63%, 71 mg (over two steps),
creamy white solid.
(S)-N-(2,3-Dihydrobenzofuran-5-yl)-4-((7-methoxy-5-oxo-
2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)-
oxy)butanamide (16). 1H NMR (400 MHz, CDCl3): δ 7.69 (s, 1H),
7.67 (d, 1H, J = 4.4 Hz), 7.52 (s, 1H), 7.48 (s, 1H), 6.99 (dd, 1H, J =
2.0, 8.4 Hz), 6.83 (s, 1H), 6.69 (d, 1H, J = 8.4 Hz), 4.55 (t, 2H, J =
8.8 Hz), 4.19−4.11 (m, 2H), 3.88 (s, 3H), 3.85−3.78 (m, 1H), 3.73−
3.67 (m, 1H), 3.61−3.54 (m, 1H), 3.18 (t, 2H, J = 8.8 Hz), 2.59−
2.54 (m, 2H), 2.32−2.21 (m, 4H), 2.10−2.02 (m, 2H). 13C NMR
(100 MHz, CDCl3): δ 170.6, 164.6, 162.6, 156.9, 150.4, 147.6, 140.7,
130.9, 127.5, 120.4, 118.4, 111.6, 110.7, 109.0, 71.4, 68.0, 56.1, 53.7,
46.7, 33.8, 31.8, 29.9, 29.6, 24.9, 24.2. HRMS m/z (+EI) calcd for
C25H27N3O5 (M)
+, 450.2023; found, 450.2024. HPLC Method A:
purity = >98%, retention time = 5.78 min. Method B: purity = >98%,
retention time = 2.95 min. Yield = 60%, 69 mg (over two steps),
transparent oil.
(S)-N-(2,3-Dihydro-1H-inden-5-yl)-4-((7-methoxy-5-oxo-
2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)-
oxy)butanamide (17). 1H NMR (400 MHz, CDCl3): δ 7.71 (s, 1H),
7.66 (d, 1H, J = 4.4 Hz), 7.52 (s, 1H), 7.14−7.12 (m, 2H), 6.82 (s,
1H), 4.21−4.09 (m, 2H), 3.89 (s, 3H), 3.83−3.77 (m, 1H), 3.73−
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01849
J. Med. Chem. 2019, 62, 2127−2139
2135
3.67 (m, 1H), 3.61−3.53 (m, 1H), 2.86 (q, 4H, 3.6, 16.8 Hz), 2.59−
2.56 (m, 2H), 2.32−2.23 (m, 4H), 2.10−2.00 (m, 4H).). 13C NMR
(100 MHz, CDCl3): δ 170.5, 164.6, 162.5, 150.4, 147.7, 145.1, 140.7,
140.2, 136.1, 124.4, 120.4, 118.1, 116.5, 111.5, 110.7, 67.9, 56.1, 53.7,
46.7, 34.0, 33.0, 32.3, 29.6, 25.6, 24.8, 24.2. HRMS m/z (+EI) calcd
for C26H29N3O4 (M)
+, 448.2233; found, 448.2231. HPLC Method A:
purity = >98%, retention time = 6.55 min. Method B: purity = >98%,
retention time = 3.33 min. Yield = 63%, 72 mg (over two steps),
creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(4-propoxyphenyl)-
butanamide (18). 1H NMR (400 MHz, CDCl3): δ 7.83 (s, 1H), 7.67
(d, 1H, J = 4.4 Hz), 7.52 (s, 1H), 7.38 (d, 2H, J = 9.2 Hz), 6.84 (s,
1H), 6.83 (d, 2H, J = 9.2 Hz), 4.19−4.10 (m, 2H), 3.89 (t, 2H, J = 6.4
Hz), 3.88 (s, 3H), 3.86−3.80 (m, 1H), 3.75−3.67 (m, 1H), 3.62−
3.55 (m, 1H), 2.59−2.53 (m, 2H), 2.33−2.22 (m, 4H), 2.10−2.00
(m, 2H), 1.83−1.75 (sex, 2H, J = 7.2 Hz), 1.03 (t, 3H, J = 7.2 Hz).
13C NMR (100 MHz, CDCl3): δ 170.5, 164.6, 162.5, 155.9, 150.5,
147.7, 140.7, 132.1, 131.0, 128.6, 128.5, 121.8, 120.4, 114.7, 111.6,
110.8, 67.8, 68.0, 56.1, 46.7, 33.8, 29.6, 24.8, 24.2, 22.6, 10.5. HRMS
m/z (+EI) calcd for C26H31N3O5 (M)
+, 466.2332; found, 466.2336.
HPLC Method A: purity = >98%, retention time = 6.57 min. Method
B: purity = >98%, retention time = 3.33 min. Yield = 65%, 77 mg
(over two steps), pale orange solid.
(S)-N-(4-Ethoxyphenyl)-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahy-
dro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide
(19). 1H NMR (400 MHz, CDCl3): δ 7.84 (s, 1H), 7.64 (d, 1H, J =
4.4 Hz), 7.49 (s, 1H), 7.36 (d, 2H, J = 8.8 Hz), 6.80 (s, 1H), 6.80 (d,
2H, J = 8.8 Hz), 4.17−4.07 (m, 2H), 3.97 (q, 2H, J = 3.2 Hz), 3.84 (s,
3H), 3.82−3.76 (m, 1H), 3.71−3.67 (m, 1H) 3.59−3.52 (m, 1H)
2.54−2.51 (m, 2H), 2.33−2.20 (m, 4H), 2.08−1.97 (m, 2H), 1.37 (t,
3H, J = 7.2 Hz). 13C NMR (100 MHz, CDCl3): δ 170.6, 164.6, 162.6,
155.6, 150.5, 147.7, 140.8, 131.1, 121.9, 120.4, 114.7, 111.5, 110.7,
68.0, 63.7, 56.1, 53.7, 46.7, 33.8, 31.0, 29.6, 29.3, 24.8, 24.2, 14.9.
HRMS m/z (+EI) calcd for C25H29N3O5 (M)
+, 452.2180; found,
452.2180. HPLC purity = >98%, retention time = 6.10 min. Method
B: purity = >98%, retention time = 3.13 min. Yield = 64%, 74 mg
(over two steps), creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(4-methoxyphenyl)-
butanamide (20). 1H NMR (400 MHz, CDCl3): δ 7.67 (d, 1H, J =
4.4 Hz), 7.59 (s, 1H), 7.52 (s, 1H), 7.38 (dd, 2H, J = 2.0, 6.8 Hz),
6.88−6.63 (m, 3H), 4.23−4.10 (m, 2H), 3.87−3.77 (m, 1H), 3.88 (s,
3H), 3.79 (s, 3H), 3.75−3.68 (m, 1H), 3.61−3.55 (m, 1H), 2.62−
2.58 (m, 2H), 2.33−2.25 (m, 4H), 2.10−2.00 (m, 2H). 13C NMR
(100 MHz, CDCl3): δ 170.5, 164.6, 162.5, 156.3, 150.4, 147.6, 140.7,
131.0, 121.9, 120.5, 114.1. 111.6, 110.8, 67.9, 56.1, 55.5, 53.7, 46.7,
33.9, 31.0, 29.6, 29.3, 24.8, 24.2. HRMS m/z (+EI) calcd for
C24H27N3O5 (M)
+, 438.2024; found, 438.2023. HPLC Method A:
purity = >98%, retention time = 5.82 min. Method B: purity = >98%,
retention time = 2.97 min. Yield = 61%, 68 mg (over two steps),
creamy white solid.
(S)-N-(4-Hydroxyphenyl)-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahy-
dro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide
(21). 1H NMR (400 MHz, (CD3)2SO): δ 9.70 (s, 1H), 9.15 (s, 1H),
7.78 (d, 1H, J = 4.4 Hz), 7.36 (dd, 2H, J = 2.0, 6.8 Hz), 7.33 (s, 1H),
6.84 (s, 1H), 6.67 (dd, 2H, J = 2.0, 6.8 Hz) 4.15−4.01 (m, 2H), 3.82
(s, 3H), 3.71−3.67 (m, 1H), 3.66−3.55 (m, 1H), 3.63−3.57 (m, 1H),
2.46−2.43 (m, 2H), 2.31−2.18 (m, 2H), 2.04−2.00 (m, 2H), 1.97−
1.92 (m, 2H). 13C NMR (100 MHz, (CD3)2SO): δ 169.8, 164.2,
163.3, 153.1, 150.2, 146.9, 140.5, 130.9, 120.8, 119.9, 119.7, 114.9,
111.1, 110.1, 68.5, 55.5, 46.3, 32.4, 32.1, 30.7, 28.8, 24.5, 23.6. HRMS
m/z (+EI) calcd for C23H25N3O5 (M)
+, 424.1867; found, 424.1867.
HPLC purity = >98%, retention time = 5.23 min. Method B: purity =
>98%, retention time = 2.65 min. Yield = 57%, 61 mg (over two
steps), creamy white solid.
(S)-N-(3,4-Dimethylphenyl)-4-((7-methoxy-5-oxo-2,3,5,11a-tet-
rahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-
butanamide (22). 1H NMR (400 MHz, CDCl3): δ 7.60 (d, 1H, J =
4.4 Hz), 7.46 (s, 1H), 7.42 (s, 1H), 7.20 (s, 1H), 7.11 (dd, 1H, J =
1.6, 7.6 Hz), 6.98 (d, 1H, J = 8.0 Hz), 6.76 (s, 1H), 4.18−4.05 (m,
2H), 3.83 (s, 3H), 3.78−3.71 (m, 1H), 3.67−3.61 (m, 1H), 3.57−
3.47 (m, 1H), 2.54−2.48 (m, 2H), 2.27−2.19 (m, 4H), 2.16 (s, 3H),
2.14 (s, 3H), 2.02−1.97 (m, 2H). 13C NMR (100 MHz, CDCl3): δ
170.5, 164.6, 162.5, 150.4, 147.7, 140.7, 137.2, 135.6, 132.6, 129.9,
121.4, 120.5, 117.5, 111.6, 110.9, 67.9, 56.1, 53.7, 46.7, 34.0, 29.6,
24.8, 24.2, 19.9, 19.2. HRMS m/z (+EI) calcd for C25H29N3O4 (M)
+,
436.2232; found, 436.2231. HPLC Method A: purity = >98%,
retention time = 6.33 min. Method B: purity = >98%, retention time
= 3.27 min. Yield = 64%, 71 mg (over two steps), creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(p-tolyl)butanamide (23).
1H NMR (400 MHz, CDCl3): δ 7.68 (s, 1H), 7.59 (d, 1H, J = 4.4
Hz), 7.44 (s, 1H), 7.30 (d, 2H, J = 8.4 Hz), 7.03 (d, 2H, J = 8.4 Hz),
6.75 (s, 1H), 4.14−4.02 (m, 2H), 3.81 (s, 3H), 3.78−3.68 (m, 1H),
3.67−3.61 (m, 1H), 3.55−3.47 (m, 1H), 2.53−2.48 (m, 2H), 2.28−
2.16 (m, 7H), 2.02−1.94 (m, 2H). 13C NMR (100 MHz, CDCl3): δ
170.6, 164.6, 162.5, 150.4, 147.7, 140.7, 135.4, 133.8, 129.4, 120.4,
120.0, 111.6, 110.8, 67.9, 56.1, 53.7, 46.7, 34.0, 31.0, 29.6, 29.3, 24.8,
24.2, 20.9. HRMS m/z (+EI) calcd for C24H27N3O4 (M)
+, 422.2074;
found, 422.2074. HPLC Method A: purity = >98%, retention time =
6.22 min. Method B: purity = >98%, retention time = 3.17 min. Yield
= 70%, 75 mg (over two steps), creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(m-tolyl)butanamide (24).
1H NMR (400 MHz, CDCl3): δ 7.88 (s, 1H), 7.67 (d, 1H, J = 4.4
Hz), 7.52 (s, 1H), 7.38 (s, 1H), 7.28 (d, 1H, J = 8.0 Hz), 7.18 (t, 1H,
J = 8.0 Hz), 6.91 (d, 1H, J = 7.2 Hz), 6.83 (s, 1H), 4.19−4.09 (m,
2H), 3.88 (s, 3H), 3.86−3.79 (m, 1H), 3.74−3.68 (m, 1H), 3.62−
3.55 (m, 1H), 2.61−2.57 (m, 2H), 2.36−2.23 (s, 7H), 2.10−2.01 (m,
2H). 13C NMR (100 MHz, CDCl3): δ 170.7, 164.6, 162.6, 150.5,
147.7, 140.7, 138.8, 138.0, 128.7, 124.9, 120.6, 120.4, 117.0, 111.6,
110.8, 67.9, 56.1, 46.7, 34.0, 29.6, 29.3, 24.8, 24.2, 21.5. HRMS m/z
(+EI) calcd for C24H27N3O4 (M)
+, 422.2074; found, 422.2074.
HPLC Method A: purity = >98% retention time = 6.15 min. Method
B: purity = >98%, retention time = 3.15 min. Yield = 68%, 73 mg
(over two steps), creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-phenylbutanamide (25).
1H NMR (400 MHz, CDCl3): δ 7.80 (s, 1H), 7.65 (d, 1H, J = 4.4
Hz), 7.50 (s, 1H), 7.49 (d, 2H, J = 8.0 Hz), 7.29 (t, 2H, J = 8.0 Hz),
7.07 (t, 1H, J = 7.6 Hz), 6.81 (s, 1H), 4.19−4.08 (m, 2H), 3.86 (s,
3H), 3.84−3.77 (m, 1H), 3.72−3.67 (m, 1H), 3.60−3.53 (m, 1H),
2.62−2.58 (m, 2H), 2.31−2.24 (m, 4H), 2.10−2.00 (m, 2H). 13C
NMR (100 MHz, CDCl3): δ 170.7, 164.6, 16.6, 150.4, 147.7, 140.7,
138.0, 129.0, 124.2, 124.5, 119.9, 111.6, 110.8, 67.9, 56.1, 53.7, 53.5,
46.7, 34.05, 29.6, 29.3, 24.8, 24.2. HRMS m/z (+EI) calcd for
C23H25N3O4 (M)
+, 408.1918; found, 408.1918. HPLC Method A:
purity = >98%, retention time = 5.93 min. Method B: purity = >98%,
retention time = 3.00 min. Yield = 70%, 73 mg (over two steps),
creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(pyridin-3-yl)butanamide
(26). 1H NMR (400 MHz, CDCl3): δ 8.82 (s, 1H), 8.51 (d, 1H, J =
2.4 Hz), 8.23 (dd, 1H, J = 1.2, 4.8 Hz), 8.14 (d, 1H, J = 7.6 Hz) 7.59
(d, 1H, J = 4.4 Hz), 7.41 (s, 1H), 7.18 (dd, 1H, J = 4.8, 8.4 Hz), 6.74
(s, 1H), 4.05−4.01 (m, 2H), 3.78−3.71 (m, 4H), 3.66−6.61 (m, 1H),
3.52−3.47 (m, 1H), 2.54−2.51 (m, 2H), 2.26−2.24 (m, 2H), 2.19−
2.15 (m, 2H), 2.02−1.95 (m, 2H). 13C NMR (100 MHz, CDCl3): δ
171.6, 164.6, 162.7, 150.4, 147.6, 144.7, 141.2, 140.7, 135.4, 127.2,
123.6, 120.3, 111.6, 110.6, 67.9, 56.0, 53.8, 46.7, 33.7, 29.5, 24.7, 24.2.
HRMS m/z (+EI) calcd for C22H24N4O4 (M)
+, 409.1870; found,
409.1866. HPLC Method A: purity = >98%, retention time = 4.67
min. Method B: purity = >98%, retention time = 2.35 min. Yield =
56%, 58 mg (over two steps), creamy white solid.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-(pyridin-4-yl)butanamide
(27). 1H NMR (400 MHz, CDCl3): δ 8.95 (s, 1H), 8.41 (d, 2H, J =
6.0 Hz), 7.64 (d, 1H, J = 4.4 Hz), 7.49 (dd, 2H, J = 1.6. 6.4 Hz), 7.46
(s, 1H), 6.79 (s, 1H), 4.10−4.06 (m, 2H), 3.81 (s, 3H), 3.79−3.76
(m, 1H), 3.71−3.67 (m, 1H), 3.57−3.52 (m, 1H), 2.60−2.56 (m,
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01849
J. Med. Chem. 2019, 62, 2127−2139
2136
2H), 2.32−2.29 (m, 2H), 2.23 (t, 2H, J = 6.4 Hz), 2.07−1.99 (m,
2H).). 13C NMR (100 MHz, CDCl3): δ 171.8, 164.6, 162.7, 150.4,
150.3, 147.6, 145.6, 140.7, 120.4, 113.6, 111.6, 110.7, 67.8, 56.0, 53.5,
46.7, 34.0, 29.7, 24.5, 24.2. HRMS m/z (+EI) calcd for C22H24N4O4
(M)+, 409.1870; found, 409.1866. HPLC Method A: purity = >98%,
retention time = 4.06 min. Method B: purity = >98%, retention time
= 2.40 min. Yield = 58%, 60 mg (over two steps), creamy white solid.
(S)-N-Cyclohexyl-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide (28). 1H
NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, J = 4.4 Hz), 7.50 (s, 1H),
6.80 (s, 1H) 5.54 (d, 1H, J = 4.0 Hz), 4.14−4.03 (m, 2H), 3.93 (s,
1H), 3.83−3.76 (m, 1H), 3.76−3.67 (m, 2H), 3.59−3.51 (m, 1H),
2.36 (t, 2H, J = 7.6 Hz), 2.38−2.32 (m, 2H), 2.33−2.28 (m, 2H),
2.20−2.15 (m, 2H), 2.08−2.01 (m, 2H), 1.84−1.80 (m, 3H), 1.67−
1.55 (m, 3H), 1.39−1.24 (m, 2H), 1.13−0.97 (m, 2H). 13C NMR
(100 MHz, CDCl3): δ 171.1, 164.6, 162.5, 150.6, 147.7, 140.8, 120.4,
111.6, 110.8, 67.9, 56.1, 53.7, 48.1, 46.7, 33.2, 31.8, 31.0, 29.6, 29.3,
25.6, 25.0, 24.9, 24.2. HRMS m/z (+EI) calcd for C23H31N3O4 (M)
+,
414.2389; found, 414.2387. HPLC Method A: purity = 93%,
retention time = 5.80 min. Method B: purity = 94%, retention time
= 3.00 min. Yield = 64%, 67 mg (over two steps), orange oil.
(S)-N-Butyl-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide (29). 1H
NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, J = 4.4 Hz), 7.49 (s, 1H),
6.79 (s, 1H), 5.95 (bs, 1H), 4.13−4.03 (m, 2H), 3.91 (s, 3H), 3.83−
3.77 (m, 1H), 3.71−3.67 (m, 1H), 3.59−3.52 (m, 1H), 3.23−3.18
(m, 2H), 2.40−2.36 (m, 2H), 2.32−2.29 (m, 2H), 2.18−2.13 (m,
2H), 2.08−2.01 (m, 2H), 1.46−1.39 (m, 2H), 1.34−1.26 (m, 2H),
0.87 (t, 3H, J = 7.2 Hz). 13C NMR (100 MHz, CDCl3): δ 172.2,
164.6, 162.5, 150.5, 147.7, 140.7, 120.3, 111.5, 110.7, 68.0, 56.1, 53.8,
46.7, 39.3, 33.0, 31.8, 29.6, 24.9, 24.2, 20.1, 13.8. HRMS m/z (+EI)
calcd for C21H29N3O4 (M)
+, 388.2231; found, 388.2224. HPLC
Method A: purity = >98%, retention time = 5.57 min. Method B:
purity = >98%, retention time = 2.85 min. Yield = 73%, 72 mg (over
two steps), orange oil.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-propylbutanamide (30). 1H
NMR (400 MHz, CDCl3): δ 7.66 (d, 1H, J = 4.4 Hz), 7.50 (s, 1H),
6.81 (s, 1H), 5.96 (bs, 1H), 4.15−4.04 (m, 2H), 3.91 (s, 3H), 3.84−
3.78 (m, 1H), 3.72−3.68 (m, 1H), 3.60−3.57 (m, 1H), 3.21−3.16
(m, 2H), 2.40−2.38 (m, 2H), 2.36−2.23 (m, 2H), 2.21−2.16 (m,
2H), 2.09−2.01 (m, 2H), 1.47 (sex, 2H, J = 7.2 Hz), 0.87 (t, 3H, J =
4.0 Hz). 13C NMR (100 MHz, CDCl3): δ 172.2, 164.6, 162.5,, 150.5,
147.7, 140.7, 120.3, 111.5, 110.7, 68.0, 56.1, 46.7, 41.2, 33.0, 29.6,
29.3, 25.0, 24.2, 22.9, 11.4. HRMS m/z (+EI) calcd for C20H27N3O4
(M)+, 374.2074; found, 374.2071. HPLC Method A: purity = >98%,
retention time = 5.33 min. Method B: purity = >98%, retention time
= 2.68 min. Yield = 64%, 61 mg (over two steps), orange oil.
(S)-N-Ethyl-4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanamide (31). 1H
NMR (400 MHz, CDCl3): δ 7.65 (d, 1H, J = 4.4 Hz), 7.49 (s, 1H),
6.80 (s, 1H), 5.98 (bs, 1H), 4.14−4.04 (m, 2H), 3.92 (s, 3H), 3.83−
3.77 (m, 1H), 3.72−3.69 (m, 1H), 3.59−3.52 (m, 1H), 3.29−3.22
(m, 2H), 2.41−2.34 (m, 2H), 2.32−2.30 (m, 2H), 2.20−2.14 (m,
2H), 2.10−1.99 (m, 2H), 1.08 (t, 3H, J = 7.2 Hz). 13C NMR (100
MHz, CDCl3): δ 172.1, 164.6, 162.5, 150.5, 147.7, 140.7, 120.3,
111.5, 110.7, 68.0, 56.1, 46.7, 34.3, 33.0, 29.6, 29.3, 24.9, 24.2, 14.8.
HRMS m/z (+EI) calcd for C19H25N3O4 (M)
+, 360.1918; found,
360.1913. HPLC Method A: purity = >98%, retention time = 5.08
min. Method B: purity = >98%, retention time = 2.55 min. Yield =
67%, 61 mg (over two steps), orange oil.
(S)-4-((7-Methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-N-methylbutanamide (32).
1H NMR (400 MHz, CDCl3): δ 7.60 (d, 1H, J = 4.4 Hz), 7.44 (s,
1H), 6.74 (s, 1H), 5.98 (bs, 1H), 4.09−3.98 (m, 2H), 3.87 (s, 3H),
3.78−3.72 (m, 3H), 3.66−3.63 (m, 1H), 3.54−3.47 (m, 1H), 2.73 (d,
3H, J = 4.8 Hz), 2.35−2.33 (m, 2H), 2.29−2.23 (m, 2H), 2.02−1.94
(m, 2H). 13C NMR (100 MHz, CDCl3): δ 172.9, 164.6, 162.5, 150.5,
147.6, 140.7, 120.4, 111.6, 110.6, 68.1, 56.1, 53.7, 46.7, 33.0, 29.6,
26.3, 24.9, 24.2. HRMS m/z (+EI) calcd for C18H23N3O4 (M)
+,
346.1761; found, 346.1757. HPLC Method A: purity = >98%,
retention time = 4.88 min. Method B: purity = >98%, retention time
= 2.47 min. Yield = 69%, 60 mg (over two steps), orange oil.
Primary CLL, JJN-3 and Healthy B and T Cell Cytotoxicity
Screening. Primary CLL cells and primary B and T cells were
obtained from patient/healthy donor blood samples using density
gradient centrifugation with Histopaque and were phenotyped for
CD3, CD5 and CD19 using an Accuri C6 ﬂow cytometer. The
primary cells were used within 24 h of sample preparation and were
maintained in Roswell Park Memorial Institute (RPMI) media (10%
foetal bovine serum (FBS), 1% glutamate and 1% pen/strep. IL-4 was
also added to primary CLL cell cultures alongside treatment with test
compounds at a concentration of 5 ng/mL.
JJN-3 cells were maintained in Dulbecco’s modiﬁed Eagle’s media
containing 20% FBS, 1% pen/strep, and 1% pyruvate at concen-
trations between 500 000 and 2 000 000 cells/mL. All cells were
maintained at 37 °C in atmospheric conditions of 5% CO2.
Cytotoxicity screenings were carried out in triplicate with these
cells at a cell density of 1 000 000 cells/mL. Cells were treated with
test compounds at a range of concentrations to establish LC50 values.
Cells were incubated with the compounds for 48 h before being
harvested. annexin V/PI positivity was then determined using the
annexin V apoptosis detection kit (eBioscience) in accordance with
the manufacturer’s instructions. Following staining with FITC labeled
annexin V and propidium iodide, samples were analyzed on the Accuri
C6 ﬂow cytometer to determine relative levels of cell death in the
sample. Prism 6 software was then used to analyze the data to obtain
dose−response curves.
Nuclear NF-κB (ELISA) Assay. 5 000 000 JJN-3 cells were treated
for 4 h with test compounds alongside untreated controls before being
harvested and spun down. Nuclear extracts were then produced using
the nuclear extraction kit purchased from Active Motif. Nuclear
extracts were stored at −80 °C before use in the NF-kB family ELISA
kit (Active Motif). Total protein levels in the nuclear extracts were
determined using a BCA protein detection kit, which allowed the
calculation of nuclear extract volume equivalent to 1 μg of total
protein. This was then added in accordance with the manufacturer’s
instructions to the ELISA plate. An optical density reading of the plate
at 450 nm was then recorded. The sample absorbance values were
then normalized with the standard curve absorbance values obtained
from recombinant NF-κB subunit protein purchased from Active
Motif. This allowed the calculation of the concentration of each NF-
κB subunit present in the nuclear extract following treatment,
compared with an untreated control.
Molecular Modeling. Double-stranded DNA type B was
generated by the NAB module of AMBER 16.0 package program,
using the template of the sequences used in the study. The PDB ﬁle
for the ligands was generated by ChemOﬃce 16.0. All of the DNA
and ligand structures were minimized by SYBYL software before
molecular docking. Molecular docking of the ligands to each of the
generated DNA sequences was performed using the SMINA
molecular docking program. All parameters were kept at their default
values. The grid box was prepared to cover the full length of the DNA
to allow the ligand molecules to explore all the possible binding sites
of DNA including the major grooves and minor grooves.
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